Received Nov 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
Prostate cancer; This is a spontaneous report received from a consumer from License Party. Other Case identifier(s): AE-021404 (BioNTech). A male patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient's relevant medical history included: "Leukemia" (not ongoing). The patient's concomitant medications were not reported. The following information was reported: PROSTATE CANCER (medically significant) with onset 29Oct2025, outcome "unknown". At the day of reporting (29Oct2025; reported by the patient's sibling who was a participant in mRNA COVID-19 vaccine clinical trials), the patient was diagnosed with prostate cancer. The patient had leukemia a few years back and worked with his doctors and COVID-19 vaccine back then too. The patient was fully cured of leukemia. They are trying and seeking the best treatment for his cancer (prostate cancer). The patient's sibling looked up and saw that the company had trials for the mRNA vaccine for prostate cancer, but it also said ended. The patient's sibling was wondering if there are available trials the patient might be able to enter to try the prostate cancer mRNA vaccine. The patient's sibling asked for information as soon as possible as the patient begins his fight with this disease. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received. BNT162b2 is under agreement with BIONTECH SE.
Medical History/Concurrent Conditions: Leukemia